Nonalcoholic steatohepatitis (NASH) is an aggressive liver disease threatening public health, however its natural history is poorly understood. Unlike ob/ob mice, Lep ∆I14/∆I14 rats develop unique NASH phenotype with steatosis, lymphocyte infiltration and ballooning after postnatal week 16. Using Lep ∆I14/∆I14 rats as NASH model, we studied the natural history of NASH progression by performing an integrated analysis of hepatic transcriptome from postnatal week 4 to 48. Leptin deficiency results in a robust increase in expression of genes encoding 9 rate-limiting enzymes in lipid metabolism such as ACC and FASN. However, genes in positive regulation of inflammatory response are highly expressed at week 16 and then remain the steady elevated expression till week 48. The high expression of cytokines and chemokines including CCL2, TNFɑ, IL6 and IL1β is correlated with the phosphorylation of several key molecules in pathways such as JNK and NF-κB.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, affecting approximately 24% of the population.(1) Depending on the presence of inflammation, it is further categorized into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH).(2) NAFLD, especially NASH, will eventually develop into liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) in some cases.(3) Historically, the severity of NAFLD can be assessed by many diagnostic modalities, including examination of demographic record, serum parameters, histopathological characteristics of liver biopsies and the emerging noninvasive methods such as magnetic resonance imaging-proton density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE).(4) However, the severity level only provides snapshot of a certain stage during the temporal progression of the disease. The natural history of NAFLD in human beings is still poorly understood due to its slow progression (5) and ethical issues.
LEPTIN is an adipokine secreted by white adipocyte tissues. Binding to its receptor (LEPR), LEPTIN can precisely regulate food intake, glucose and lipid metabolism, energy homeostasis, immune system, reproduction, etc. (6, 7) Leptin deficient ob/ob mice (8) have been discovered decades before the gene Leptin was characterized by Friedman's laboratory (6) . ob/ob mice are widely used as NAFLD model to mirror the human disease with obesity, hyperglycaemia, and hyperinsulinaemia. (9) But it should be noted that ob/ob mice do not develop spontaneous NASH. (10, 11) Therefore, little is known about LEPTIN function during NASH progression although it is a proinflammatory factor (12) and required for the development of fibrosis in NASH (13) .
We previously generated Leptin deficient (Lep ∆I14/∆I14 ) rats by CRISPR technology. (14) Interestingly, we found that Lep ∆I14/∆I14 rats display distinctive NASH phenotypes, which needs to be further characterized.
To study the pathogenesis and progression of NAFLD, many animal models were generated by genetic manipulation and/or dietary induction. (9) (10) (11) 15) However, the previous studies mainly focused on the endpoint when certain histopathological phenotype was observed, and neglected the temporal progression of NAFLD.
Therefore, we used Lep ∆I14/∆I14 rats as a NASH model and performed a long-term (i.e., 4 to 48 postnatal weeks) integrated transcriptomic analysis, aiming to reveal the temporal dynamics of hepatic gene expression due to LEPTIN deficiency and shed light on understanding the natural history of NASH in human beings.
Materials and Methods

Animals
Rats and mice were kept in a 12-h light, 12-h dark cycle with ad libitum access to regular chow food and water. The controls were littermates. B6/JNju-Lep em1Cd25 /Nju mice were purchased from Nanjing Biomedical Research Institute of Nanjing University (Cat#T001461). All the protocols were in accordance with the guidelines of Tongji University's Committee on Animal Care and Use. All the experimental procedures as described below were approved by the animal experiment administration committee of Tongji University (# TJLAC-016-021). PharmaLegacy Laboratories (Shanghai) Co., Ltd performed a pre-screening of Macaca fascicularis for spontaneous NAFLD. All procedures related to Macaca fascicularis were approved by PharmaLegacy Laboratories' IACUC and followed the guidelines of Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
Serum biochemical analyses
The animals were fasted for 16 h and blood was collected and left to clot for 1 h at room temperature. Serum was obtained after centrifugation. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined by using the spectrometric kits (Sigma Diagnostics). Triglyceride, high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) were examined by Adicon Central Lab. Serum IL1β was detected by Elisa kit (Boster Biological Technology).
Histological analyses
Liver samples of the animals were collected and fixed according to the routine methods for hematoxylin and eosin (HE) staining, Oil red O staining, Sirius red staining, and IHC respectively. The detailed information of the antibodies for IHC was summarized in table S1.
RT-PCR
Total RNA was extracted from snap-frozen liver samples using TRIzol (Life Technologies) according to the manufacturer's instructions. The complementary DNA was generated from 2 µg total RNA by RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). Quantitative PCR (qPCR) was performed using TB GreenTM Premix Ex TaqTM II (TaKaRa, RR820A) on QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems). PCR primers were designed to specifically amplify genes of interest (table S2) . Quantitative polymerase chain reaction (qPCR) was performed with β-Tubulin as internal control.
Western blot
Total protein was extracted from snap-frozen liver samples using RIPA lysis buffer (EpiZyme, PC104) with protease inhibitors (EpiZyme, GRF101) and phosphatase inhibitors (EpiZyme, GRF102). Western blot was performed following the routine method. The antibodies were listed in table S1. All western blots were normalized to β-Tubulin for each sample.
RNA-seq and bioinformatics
Total RNA was extracted from snap-frozen liver samples using TRIzol (Life Technologies) according to the manufacturer's instructions. RNA purity was checked using the Nano Photometer spectrophotometer (IMPLEN). RNA concentration was measured using Qubit RNA Assay Kit in Qubit 2.0 Flurometer (Life Technologies).
RNA integrity was assessed using the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies). Library construction was done using NEBNext and NASH were retained from the previous study (17) .
Accession numbers. The accession number for the rat RNA-seq data generated in this study is GSE124002.
Statistical Analyses
At each time point, the data from Lep ∆I14/∆I14 rats were compared to the WT controls by t test. P value of <0.05 was defined as the level of significance, and all graphs and analyses were performed using GraphPad Prism (version 6; GraphPad Software Inc., La Jolla, CA).
Results
Leptin deficiency leads to NASH phenotypes in rats
Lep ∆I14/∆I14 rats share many similar phenotypes with ob/ob mice, such as obesity, hyperglycaemia, hyperinsulinemia, NAFLD, and infertility. (14) Our previous histopathological examination showed that NAFLD starts at postnatal week 8. (14) Consistently, body weight and relative liver weight of Lep ∆I14/∆I14 rats were significantly higher than those of their wild-type (WT) littermates after 8 postnatal weeks (fig. S1A). We also observed the increase in serum parameters such as triglyceride, high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) (fig. S1A). Interestingly, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels did not follow a trend of rectilinear increase but have an inflection point at postnatal week 16 ( fig. S1A ), suggesting that NASH related inflammation develops but is restricted at certain level afterwards. To further characterize NASH phenotypes in Lep ∆I14/∆I14 rats, we did hematoxylin-eosin (HE) and Oil Red O staining of liver sections prepared at different time points during disease progression ( Fig. 1A) . Simple steatosis was developed after week 8, however, it was at week 16 that emerged the stereotypic NASH phenotypes including steatosis, lymphocyte infiltration and ballooning ( Fig. 1B-D) . MPO + neutrophil infiltration started to be observed at week 16 ( Fig. 1E ). Using the NASH scoring system (table  S3 ) (16) , we found that Lep ∆I14/∆I14 rats indeed developed NASH (NASH score≥5) which reached a plateau after week 16 ( Fig. 1F ). We did not see fibrosis in Lep ∆I14/∆I14 rats at any time points through week 48 (fig. S1B).
As previous research showed that ob/ob mice do not develop spontaneous NASH (10, 11) , we performed the independent experiments to validate this in our laboratory.
Similar to Lep ∆I14/∆I14 rats, Leptin deficient mice had significantly higher body weight 
Integrated transcriptomic analysis show that NASH progression involves distinct gene regulation of lipid metabolism and hepatic inflammation
To understand the disease progression at systemic level, some pioneers have investigated the transcriptome of liver biopsies from NAFLD patients at mild, medium and severe stages. (17, 18) However, the severity levels in different individuals do not reflect the temporal progression of the disease in a particular person. Therefore, we decided to build a more complete picture of NASH progression by using this unique model of Lep ∆I14/∆I14 rats. We performed RNA-sequencing (RNAseq) of the liver samples from WT and Lep ∆I14/∆I14 rats at postnatal 4-week, 8-week, 16 -week, 32-week and 48-week respectively. Over all, the hepatic transcriptome showed dynamic changes at different time points ( Fig. 3A) . At week 4, the expression profiles of WT controls and Lep ∆I14/∆I14 rats were very similar and cluster together, which is in line with the histopathological data ( Fig. 1A) that Lep ∆I14/∆I14 rats have not yet developed NAFLD by week 4. From week 8 to week 32, the expression profiles of WT controls and Lep ∆I14/∆I14 rats clustered separately, implying a temporal NAFLD progression. It should be noted that the expression profiles of WT controls at week 48 are clustered closely to that of Lep ∆I14/∆I14 rats (Fig. 3A) , probably due to the agingrelated NAFLD in WT controls ( Fig. 1A) . We then identified the differentially To answer this question, we first profiled the dynamic expression of the genes with functions related to lipid metabolism and inflammation respectively (fatty acid biosynthetic process [GO:0006633] and positive regulation of inflammatory response [GO:0050729]). As expected, the inflammation-related genes in Lep ∆I14/∆I14 rats started to be expressed significantly higher than WT at week 16 (p<0.05) and then remained the steady elevated expression (p<0.05) till week 48 ( Fig 3D) . To our surprise, the expression levels of lipid-metabolism related genes have no significant difference between Lep ∆I14/∆I14 and WT rats for each time point, and have no precipitous fluctuation across all time points (Fig. 3D ). As liver steatosis is morbid accumulation of triglyceride (TAG) in hepatocytes, we selected 9 genes which encode well-known essential enzymes including ACC and FASN for TAG synthesis. The expression of these 9 genes displayed an elevating trend in both WT and Lep ∆I14/∆I14 rats, however, was significantly higher in Lep ∆I14/∆I14 rats (Fig. 3E ). All the 9 genes had a dynamic expression pattern during NASH progression (Fig. 3F) , some of which were verified by qRT-PCR ( fig. S4A ). This suggests that liver steatosis is correlated with the elevated expression of a subgroup of rate-limiting enzymes, which may provide combinatory therapeutic targets for reducing fat accumulation in liver. In conclusion, our data support that NASH progression is a continuous process which coordinates distinct gene expression involving in lipid metabolism and inflammation.
Restricted hepatic inflammation in Lep ∆I14/∆I14 rats is determined by the inflammation related genes, pathways and immune cell infiltration
To explain the restricted inflammation after week 16 during NASH progression in Lep ∆I14/∆I14 rats, we decided to investigate the inflammation related genes, pathways and immune cell infiltration. As demonstrated above (Fig. 3D ), many proinflammation genes started to be expressed with a high level at week 16 in Lep ∆I14/∆I14 rats (Fig. 4A ). We also examined the expression of several inflammation related genes including Ccl2, Tnfɑ and Il6 by qRT-PCR ( Fig. 4B ) and/or Western blot ( fig. S4B and C), and found that their expression levels indeed peaked at week 16. Meanwhile, serum IL1β level was elevated at week 16 and remained at a steady level afterwards ( Fig. 4C ). It's well known that inflammatory processes are mainly regulated by conserved signaling pathways through the phosphorylation of several key molecules such as JNK and NF-κB (19, 20) . So we examined the expression and posttranslational modification of these molecules at different time points by Western blot ( Fig. 4D and E) . We found that the activated (phosphorylated) form of JNK ( Fig. 4D) was markedly higher after week 16 in Lep ∆I14/∆I14 rats compared to the WT controls.
The elevation of phosphorylated P65 was observed as soon as week 8 (Fig. 4D) , which is in line with the fact that NF-κB mediated signaling is required for the activation of pro-inflammation gene expression.
Macrophage polarization of pro-inflammatory M1 (classically activated macrophages)
and anti-inflammatory M2 (alternatively activated macrophages) also contributes to liver inflammation and injury (21) . Interestingly, we found that M2 related gene Arg1 was downregulated in the livers of Lep ∆I14/∆I14 rats at week 16, while M1 related gene Inos (Nos2) was upregulated, which was validated by qRT-PCR ( Fig. 5A) . At protein level, M2 marker CD163 was reduced at week 16 (Fig. 5B) , while M1 marker CD11B (22, 23) was increased (Fig. 5C ). Since inflammation in liver involves infiltration of distinct types of immune cells (24, 25) , this suggested that NASH progression in Lep ∆I14/∆I14 rats may also involve immune cell infiltration. Indeed, we observed an increase of CD8 + T cells and CD68 + hepatic macrophages ( Fig. 5D ) in addition to MPO + neutrophil infiltration (Fig. 1E ). M2 to M1 polarization was evidenced by the results that the number of inflammatory monocyte-derived macrophages (CCR2 + ) and
M1 macrophages/dendritic cells (CD11C + ) was significantly higher in the livers of
Lep ∆I14/∆I14 rats after week 16, while that of M2 macrophages (CD163 + ) was less than the controls (Fig. 5D, fig. S5 ). The temporal examination of immune cell infiltration from week 4 to week 48 is included in fig. S5 . As stated above, such phenotypes were not observed in Leptin deficiency mice raised with the same condition (Fig. 2, fig.   S2 ). Taken together, hepatic inflammation in Lep ∆I14/∆I14 rats is evoked but restricted at certain level since week 16, which results from combinatory effects of gene expression, inflammatory signaling pathways and immune cell infiltration.
Lep ∆I14/∆I14 rats share more homologous genes with NASH patients than previously established mouse models
As stated above, Lep ∆I14/∆I14 rats develop NASH with a unique progression pattern.
However, is the molecular etiology of NASH in Lep ∆I14/∆I14 rats evolutionally conserved and similar to that in human beings? To answer this question, we compared the DEGs in Lep ∆I14/∆I14 rats across stages (Fig. 3B ) to those DEGs in human beings with healthy obesity (HO), NAFLD, and NASH from the previous study.(26) There were 42 DEGs that were significantly and concordantly regulated in both Lep ∆I14/∆I14 rats at week 16 and human NASH (Fig. 6A) . In contrast, there were maximal 18 DEGs in the mouse models (26) . This indicates that Lep ∆I14/∆I14 rats were better than mouse models to match human NASH at the molecular level of gene expression. Of note, none of these DEGs were common across all the time points ( fig. S6 ). The most overlapped DEGs include lipid metabolism related genes such as Fabp4 and Fasn, and inflammation related genes such as Inhbe (fig. S6 ). We next examined the hepatic gene expression in Lep ∆I14/∆I14 rats and mouse models at the functional level. We identified differentially regulated pathways by GSEA analysis (27) in Lep ∆I14/∆I14 rats and mouse models, respectively. Comparison analysis found that 20 pathways were significantly and concordantly regulated in both Lep ∆I14/∆I14 rats at week 16 and human NASH (Fig. 6B) . In contrast, there were 24 in WTD mice which share the most pathways with human NASH (26) . This implies that both Lep ∆I14/∆I14 rats and WTD mice similarly match human NASH at the functional level. PharmaLegacy Laboratories (Shanghai) has initially screened 41 crab-eating monkeys for spontaneous NAFLD models (36 NAFLD and 5 healthy controls). Although these 36 NAFLD monkeys showed mild NAFL phenotypes with higher body weight, liver triglyceride, and histological simple steatosis, there was no significant difference in inflammation-related serum parameters (e.g., AST and ALT) or histological fibrosis compared to the controls (data not shown). So we wondered if transcriptome analysis can distinguish the monkeys' mild NAFL phenotype from that of the severe NASH patients. We randomly chose 3 NAFLD and 3 control monkeys and analyzed their hepatic gene expression by RNA-seq (Their histological examination are shown in fig. S7 , and serum parameters in table S5.). We found that the NAFLD monkeys shared as few as 5 DEGs (up-regulated Fasn and Kcnj3; down-regulated Hal, P4ha1 and Slc16a7) with NASH patients, which was consistent with their mild NAFL phenotypes as described above. In addition, this suggests that a suitable NASH model is not determined by how closely the chosen species is related to human beings, but rather determined by whether it can faithfully model NASH progression in human beings to the greatest extent. Taken together, Lep ∆I14/∆I14 rats can serve as a useful NASH model as their hepatic transcriptome reflects NASH progression in humans more closely than other reported rodent models.
Lep ∆I14/∆I14 rats have potential to evaluate drug targets at transcriptional level
Many drugs for potential treatment of NASH are in clinical trials, although none have been approved by FDA yet. (28, 29) So we asked if Lep ∆I14/∆I14 rats can be used to evaluate the drug targets, at least those in clinical trials. In the hepatic targets (28, 29) excluding non-detected Ccr2 and Sirt1, agonist targeting genes such as Fxr (Nr1h4) and Pparα /δ /γ were down-regulated at most of the time points while antagonist targeting genes such as Scd1, Acc (Acaca), Aoc3, Casp3 and Galectin3(Lgals3) were up-regulated ( Fig. 6C) . Fgf21 that encodes an endocrine sensor for nutrition context is upregulated as previously reported (30) . This suggests that the pharmacologic agents targeting these genes may be pre-clinically tested in Lep ∆I14/∆I14 rats. Some targets could not be tested in Lep ∆I14/∆I14 rats. These targets included Ccr5, Khk, and Hcar2 (Niacr1) which did not show expected correlation. Tlr4 mRNA level did not correlate well with its protein level ( fig. S4C ). Ask2 (Map3k6) instead of Ask1 (Map3k5) seemed to be up-regulated in Lep ∆I14/∆I14 rats (Fig. 6C) . Nevertheless, Lep ∆I14/∆I14 rats are suitable for evaluation of many drug targets at transcriptional level and thus hold promise for screening potential biomarkers and treatment of NASH.
Discussion
We discovered Lep ∆I14/∆I14 rats as a new animal model to study human NASH. For the past decades, many animal models have been created to study NASH. Nowadays, the drug development usually targets specific molecules. The molecular etiology, especially the spatial and temporal gene expression, should be fully characterized in the animal models before the pre-clinical examination of potential drugs. Unfortunately, the temporal progression of the disease is still not well investigated in most of the animal models. Lep ∆I14/∆I14 rats develop spontaneous NASH phenotypes, which makes the experiment less time and labor consuming.
Given that rats are widely used in pharmacology and toxicology (32) , revealing the natural history of NASH in Lep ∆I14/∆I14 rats will greatly facilitate further usage of this model to screen new drugs and treatment for NASH.
There are many hypotheses on the natural history of NASH, including ''two hit'' model (33) and "the multiple parallel hits hypothesis" (34) . Using Lep ∆I14/∆I14 rats, we are able to examine the natural history of NASH at transcriptional level (Fig. 7) .
Although we cannot exclude other pathways which may also contribute, more or less, to NASH progression, we focused on distinct gene expression patterns in two major pathways such as lipid metabolism and inflammation. In Lep ∆I14/∆I14 rats, TAG accumulation in liver is correlated with increase in expression of genes encoding ratelimiting enzymes in lipid metabolism instead of the entire fatty acid biosynthesis ( Fig.   7 ). Interestingly, the expression of hepatic inflammation related genes does not increase rectilinearly but is elevated and maintained at a high level after week 16, which is associated with the activation of JNK and NFkB pathways and immune cell infiltration (Fig. 7) . The present work focuses on hepatic gene expression, but we perceive that many other tissues and organs must be involved in hepatic phenotypes of NASH, which should be further addressed using appropriate models.
As a pro-inflammatory factor, LEPTIN plays essential roles in regulation of hepatic inflammation. Neither ob/ob mice nor Lep ∆I14/∆I14 rats develop fibrosis, since LEPTIN is required for the development of fibrosis in NASH (13) , which is likely associated with activation of Stellate cells (35) and up-regulation of norepinephrine (36) .
However, hepatic inflammation in Lep ∆I14/∆I14 rats is kept higher than their mouse counterparts probably due to species difference. Previous research observed that LEPTIN resistance is present in NAFLD patients, however serum LEPTIN level does not correlate with NASH progression.(37) Indeed, our data suggest that the impairment of LEPTIN signaling maintains a restricted level of hepatic inflammation, which may also explain why only about 20% NAFLD patients develop NASH.(5) (28) LEPTIN signaling pathway may serve as an evolutionary protection mechanism against tissue damage from inflammation when excess nutrient intake is inevitable and irreversible. Therefore, we should carefully consider overdiagnosis/overtreatment of NAFLD as pointed out by Rowe (5) recently. Table S1. The antibody information used in IHC and Western blot.
